ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$16.94 USD
-0.08 (-0.47%)
Updated May 1, 2024 04:00 PM ET
After-Market: $16.92 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for ALX Oncology Holdings Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 183 | 266 | 364 | 434 | 9 |
Receivables | 0 | 0 | 0 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 5 | 3 | 2 | 0 |
Total Current Assets | 189 | 271 | 367 | 436 | 10 |
Net Property & Equipment | 4 | 4 | 1 | 0 | 1 |
Investments & Advances | 35 | 17 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 15 | 15 | 12 | 0 | 0 |
Total Assets | 243 | 306 | 380 | 436 | 11 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 8 | 4 | 0 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 27 | 19 | 10 | 6 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 2 | 0 | 0 |
Total Current Liabilities | 36 | 28 | 15 | 6 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 10 | 9 | 0 | 0 | 5 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 7 | 5 | 2 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 70 |
Total Liabilities | 53 | 43 | 17 | 6 | 81 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 676 | 590 | 565 | 548 | 2 |
Retained Earnings | -486 | -325 | -202 | -119 | -73 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 190 | 263 | 363 | 430 | -71 |
Total Liabilities & Shareholder's Equity | 243 | 306 | 380 | 436 | 11 |
Total Common Equity | 190 | 263 | 363 | 430 | -71 |
Shares Outstanding | 49.80 | 40.70 | 40.50 | 37.10 | NA |
Book Value Per Share | 3.81 | 6.47 | 8.96 | 11.59 | 0.00 |
Fiscal Year End for ALX Oncology Holdings Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 183 | 190 | 213 | 228 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 6 | 9 | 7 | 5 |
Total Current Assets | NA | 189 | 199 | 220 | 233 |
Net Property & Equipment | NA | 4 | 4 | 4 | 4 |
Investments & Advances | NA | 35 | 6 | 12 | 28 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 15 | 11 | 11 | 13 |
Total Assets | NA | 243 | 220 | 246 | 278 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 9 | 13 | 4 | 10 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 27 | 22 | 13 | 11 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 0 | 0 | 1 |
Total Current Liabilities | NA | 36 | 35 | 18 | 22 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 10 | 10 | 10 | 9 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 7 | 6 | 6 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 53 | 51 | 33 | 38 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 676 | 610 | 603 | 596 |
Retained Earnings | NA | -486 | -441 | -390 | -356 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 190 | 169 | 213 | 240 |
Total Liabilities & Shareholder's Equity | NA | 243 | 220 | 246 | 278 |
Total Common Equity | 0 | 190 | 169 | 213 | 240 |
Shares Outstanding | 50.10 | 49.80 | 41.10 | 40.80 | 40.80 |
Book Value Per Share | 0.00 | 3.81 | 4.11 | 5.21 | 5.89 |